List of Excipients in Branded Drug VOGELXO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Upsher-Smith Laboratories LLC	VOGELXO	testosterone	0245-0871	ALCOHOL
Upsher-Smith Laboratories LLC	VOGELXO	testosterone	0245-0871	CARBOMER COPOLYMER TYPE B
Upsher-Smith Laboratories LLC	VOGELXO	testosterone	0245-0871	CARBOMER HOMOPOLYMER TYPE C
Upsher-Smith Laboratories LLC	VOGELXO	testosterone	0245-0871	DIISOPROPYL ADIPATE
Upsher-Smith Laboratories LLC	VOGELXO	testosterone	0245-0871	GLYCERIN
Upsher-Smith Laboratories LLC	VOGELXO	testosterone	0245-0871	METHYL LAURATE
Upsher-Smith Laboratories LLC	VOGELXO	testosterone	0245-0871	OLEYL ALCOHOL

VOGELXO Excipient Strategy and Commercial Opportunities: Testosterone Gel Formulation Analysis

Last updated: August 25, 2026

VOGELXO is a testosterone 1% topical gel whose commercial value depends on dermal absorption, low transfer risk, manufacturing consistency, packaging, and patient adherence. Its core excipient system is conventional for hydroalcoholic testosterone gels: alcohol, water, carbomer, isopropyl myristate, and sodium hydroxide. The strongest commercial opportunities are differentiated delivery, reduced transfer, improved skin tolerability, unit-dose convenience, and supply-chain economics rather than a simple reformulation of the active ingredient. [1]

What is VOGELXO and how does its formulation work?

VOGELXO is a prescription testosterone gel indicated for replacement therapy in adult males with testosterone deficiency associated with an underlying medical condition. The product is administered topically, allowing testosterone to diffuse through the skin into systemic circulation. [1]

VOGELXO product profile

Attribute	VOGELXO profile
Active ingredient	Testosterone
Dosage form	Topical gel
Strength	1%
Route	Transdermal
Regulatory sponsor	Upsher-Smith Laboratories
FDA application	NDA 203098
Primary use	Testosterone replacement therapy
Controlled-substance status	Testosterone is a Schedule III controlled substance in the U.S.
Key commercial risks	Transfer to others, variable absorption, skin irritation, alcohol flammability, adherence

The formulation uses a hydroalcoholic gel vehicle. Alcohol supports testosterone solubilization and evaporates after application, while carbomer creates the gel structure. Isopropyl myristate acts as an emollient and can influence skin feel and drug partitioning. Sodium hydroxide neutralizes the carbomer and adjusts viscosity and pH. Purified water completes the vehicle system. [1]

What excipients are used in VOGELXO?

The FDA prescribing information identifies the inactive ingredients as alcohol, carbomer 980, isopropyl myristate, sodium hydroxide, and purified water. [1]

Functional role of each excipient

Excipient	Primary function	Formulation impact	Commercial relevance
Alcohol	Solvent and volatile vehicle	Supports testosterone solubility and rapid drying	Creates flammability, odor, and skin-drying concerns
Carbomer 980	Gelling and rheology agent	Controls viscosity, spreadability, and residence time	Affects manufacturing robustness and patient acceptance
Isopropyl myristate	Emollient and penetration-supporting excipient	Influences skin feel and partitioning into the stratum corneum	May improve sensory performance but can affect irritation and transfer
Sodium hydroxide	Neutralizing agent and pH adjuster	Activates carbomer viscosity and controls pH	Small concentration changes can materially affect rheology
Purified water	Aqueous vehicle	Supports gel formation and processing	Requires microbial and water-system controls

The excipient system is commercially important because topical testosterone performance is determined by the interaction between drug concentration, solvent evaporation, viscosity, thermodynamic activity, skin hydration, and application behavior. A formulation with the same testosterone concentration can produce a different absorption profile if its vehicle changes.

How strong is the VOGELXO excipient strategy?

The existing strategy is technically credible but not strongly differentiated. It uses well-established excipients with broad pharmaceutical precedent. That supports manufacturing and regulatory familiarity, but it limits the opportunity to obtain broad composition-of-matter protection around the vehicle.

Strengths

• Established hydroalcoholic gel architecture.
• Simple raw-material bill and conventional processing.
• Low excipient complexity.
• Fast drying after application.
• Familiar patient-use profile.
• Potentially efficient scale-up and contract manufacturing.

Weaknesses

• Alcohol can dry or irritate skin.
• Alcohol-based products can create odor and flammability concerns.
• Topical testosterone has a transfer risk to women and children.
• Absorption can vary with application site, washing, skin condition, and patient technique.
• Carbomer viscosity is sensitive to neutralization, electrolyte exposure, and processing conditions.
• Isopropyl myristate can affect both skin feel and permeability.
• The formulation offers limited obvious differentiation from other testosterone gels.

A patent estate focused only on conventional carbomer, alcohol, water, and isopropyl myristate would generally face a narrower inventive-step position than a formulation that demonstrates a defined pharmacokinetic, dermatological, transfer-reduction, or adherence advantage.

What formulation patents could protect a VOGELXO follow-on product?

The highest-value formulation claims would link excipient composition to a measurable clinical or pharmaceutical performance result.

Potential patentable claim areas

Low-transfer testosterone gel

A formulation could target reduced testosterone transfer after drying or after skin contact. Relevant claim parameters could include:

• Defined testosterone-to-solvent ratio.
• Specific polymer concentration.
• A film-forming polymer system.
• Reduced testosterone release from the dried film.
• Lower transfer to clothing or contact skin.
• Defined wash-off resistance.

Transfer reduction is commercially attractive because accidental exposure is a central safety concern in testosterone replacement therapy. A patent would be stronger if supported by standardized transfer testing rather than subjective claims about reduced contact risk.

Alcohol-reduced or alcohol-free formulations

An alcohol-free or low-alcohol formulation could target:

• Lower skin irritation.
• Lower burning or stinging.
• Better use on dry or sensitive skin.
• Improved acceptability for chronic treatment.
• Reduced flammability warnings.

The technical challenge is maintaining testosterone solubility and consistent delivery without relying on a high level of volatile alcohol. Candidate systems could include glycols, glycerol derivatives, solubilizing surfactants, lipidic vehicles, or polymeric dispersions. Each alternative creates new tolerability and absorption questions.

Improved skin tolerability

A formulation could use a lower-irritation vehicle, buffering system, emollient combination, or barrier-supportive excipient. Commercial claims would require evidence showing lower irritation without reducing testosterone exposure.

Potential differentiators include:

• Lower erythema and dryness scores.
• Lower transepidermal water loss.
• Reduced stinging during repeated use.
• Improved use on the upper arms, shoulders, or torso.
• Lower discontinuation rates linked to local reactions.

Controlled-drying or film-forming systems

A polymer system could extend residence time and reduce run-off. Suitable claims might cover:

• Drying time.
• Film strength.
• Spreadability.
• Drug release from the dried film.
• Resistance to removal by clothing or light washing.
• Reduced transfer following drying.

These claims are more defensible when the formulation has a defined rheology and a demonstrated relationship between film properties and testosterone delivery.

Metered-dose delivery

A pump or metering device can protect a formulation through device-and-drug combination claims. Commercially useful attributes include:

• Consistent testosterone dose per actuation.
• Lower dosing variability.
• Less product waste.
• Improved portability.
• Reduced hand contact with the formulation.
• Better adherence tracking.

Device claims may be more valuable than excipient claims if the active formulation is difficult to differentiate. The combination of a specific gel rheology with a calibrated pump can create a practical barrier to substitution.

What FDA regulatory issues affect VOGELXO excipient changes?

A material change to the VOGELXO vehicle can affect product quality, bioequivalence, local tolerability, and systemic exposure. The regulatory path depends on whether the sponsor pursues a generic equivalent, a reformulated product, a new dosage form, or a new drug application.

Generic or substitutable product

A product seeking approval as a generic testosterone gel generally must address:

• Pharmaceutical equivalence.
• Bioequivalence.
• Drug product quality.
• Container-closure performance.
• Drug release and permeation.
• Local tolerability.
• Application-site considerations.
• Labeling and safety requirements.

For topical products, conventional plasma pharmacokinetic studies may not fully characterize local product performance. FDA’s topical-product guidance discusses comparative physicochemical, structural, product-performance, and, where relevant, in vitro permeation testing. [2]

Reformulated branded product

A reformulated VOGELXO product with a new excipient system may require a supplemental application if it remains within the approved product framework. A materially different formulation, delivery system, indication, or dosing profile could require a new NDA or another regulatory pathway.

Key development studies would likely include:

1. Comparative physicochemical characterization.
2. Viscosity and rheology testing.
3. Assay and content uniformity.
4. In vitro release testing.
5. In vitro permeation testing.
6. Skin irritation and sensitization assessment.
7. Alcohol evaporation and drying-time analysis.
8. Transfer testing.
9. Stability in the commercial package.
10. Human pharmacokinetic and clinical bridging studies where required.

FDA’s product-specific guidance and application-specific review history should control the final development plan. [2,3]

What is the Orange Book status of VOGELXO?

The FDA Orange Book is the controlling source for approved drug products, therapeutic-equivalence evaluations, patents, and exclusivity information. VOGELXO should be assessed through its NDA record and current Orange Book listings rather than through third-party patent summaries. [3]

Orange Book review points

A commercial diligence review should verify:

Issue	Relevance
NDA holder	Confirms the regulatory owner
Active ingredient and strength	Establishes the reference product scope
Dosage form	Determines the relevant generic product category
Therapeutic-equivalence codes	Indicates substitutability status
Listed patents	Identifies Orange Book patent barriers
Exclusivity entries	Determines remaining regulatory protection
Discontinued status	Distinguishes commercial discontinuation from withdrawal for safety or efficacy
Reference-product designation	Affects ANDA strategy

The presence of a listed patent does not establish that the patent will survive Paragraph IV litigation. Conversely, the absence of a listed patent does not eliminate non-Orange Book risks involving manufacturing methods, devices, trade secrets, or non-listed formulation claims.

When does VOGELXO lose exclusivity?

VOGELXO exclusivity must be separated into regulatory exclusivity, Orange Book patent protection, and practical commercial protection.

Regulatory exclusivity

The relevant FDA exclusivity period depends on the application type, approval history, and any later-approved indications or formulations. The approval date alone does not establish the current remaining exclusivity period. The Orange Book and FDA approval records control this analysis. [3]

Patent exclusivity

Potential patent categories include:

• Drug formulation patents.
• Gel vehicle patents.
• Container-closure or dosing-device patents.
• Manufacturing-process patents.
• Method-of-use patents.
• Patents directed to transfer reduction or application-site restrictions.

Formulation and method-of-use patents may have different expiration dates and may not all be eligible for Orange Book listing. Patent-term adjustment, patent-term extension, terminal disclaimers, and post-grant proceedings can alter the effective protection period.

Which companies are challenging VOGELXO?

A definitive challenger list requires current FDA Orange Book data, ANDA litigation filings, and Paragraph IV notices. The principal competitive set is expected to include manufacturers of testosterone gels and other testosterone replacement products, including generic manufacturers and branded developers of alternative topical, injectable, buccal, nasal, and oral products.

The relevant competitors are not limited to products with the same strength. A testosterone gel may lose share to:

• Generic testosterone gel 1%.
• Testosterone gel 1.62%.
• Testosterone injections.
• Long-acting testosterone undecanoate injections.
• Testosterone pellets.
• Testosterone nasal products.
• Oral testosterone undecanoate products.
• Compounded topical testosterone.

Competition therefore depends on convenience, insurance coverage, monitoring burden, transfer risk, dosing frequency, and prescriber preference.

What Paragraph IV risks exist for VOGELXO?

An ANDA applicant can challenge an Orange Book-listed patent by making a Paragraph IV certification. The reference-product sponsor can then file patent litigation, generally creating a 30-month stay of FDA approval if the statutory conditions are met. [4]

Key Paragraph IV risk factors

• Whether VOGELXO has active listed patents.
• Whether those patents cover the formulation, use, or delivery device.
• Whether the proposed generic is therapeutically equivalent.
• Whether the generic changes excipients or packaging.
• Whether a non-infringement position is credible.
• Whether invalidity arguments target obviousness, enablement, written description, or anticipation.
• Whether the sponsor has settled earlier challenges.
• Whether the product has sufficient commercial value to justify litigation.

For topical testosterone, litigation risk can extend beyond active ingredient claims. A challenger may need to design around gel rheology, dose delivery, application instructions, or device claims even if the formulation appears chemically simple.

What manufacturing and intellectual-property barriers affect VOGELXO?

The main manufacturing barriers are process control and scale-up reproducibility rather than unusual active-ingredient chemistry.

Critical process parameters

• Carbomer dispersion and hydration.
• Order of excipient addition.
• Mixing shear.
• Neutralization rate.
• Final pH.
• Viscosity profile.
• Alcohol-loss control.
• Deaeration.
• Filling accuracy.
• Container compatibility.
• Homogeneity during storage.

Small changes in neutralization or alcohol content can alter viscosity, evaporation, spreadability, and testosterone release. A robust process should define acceptable ranges for each critical parameter and link those ranges to product-performance specifications.

Trade-secret opportunities

A sponsor may protect manufacturing know-how through trade secrets involving:

• Mixing sequence.
• Temperature controls.
• Alcohol handling.
• Deaeration.
• Carbomer neutralization.
• Filling conditions.
• In-process viscosity controls.
• Cleaning validation.
• Packaging-line yield.

Trade-secret protection is useful where the process is difficult to reverse-engineer and where public patent disclosure would assist competitors.

What commercial opportunities exist for VOGELXO excipients?

1. Low-transfer reformulation

A lower-transfer formulation could command value with patients, prescribers, and payers if it reduces accidental exposure and simplifies post-application precautions. The strongest product would combine low transfer with rapid drying and equivalent testosterone exposure.

2. Skin-tolerability positioning

A formulation with lower alcohol content or a more protective emollient system could target long-term users who discontinue because of dryness, burning, or irritation. The commercial opportunity depends on demonstrating improved tolerability rather than merely changing the inactive-ingredient list.

3. Metered pump presentation

A pump can improve dose consistency and reduce product handling. It may also support adherence programs and refill analytics. Device differentiation is particularly relevant when multiple generic gels compete on price.

4. Unit-dose packaging

Single-use packets can improve portability and dose control. They also limit repeated container opening and may reduce contamination. The tradeoff is higher packaging cost and greater material use.

5. Institutional and specialty-pharmacy supply

A stable, low-waste presentation could target urology practices, endocrinology clinics, specialty pharmacies, and health systems. Contract packaging and private-label opportunities may be attractive if the product can meet controlled-substance distribution and serialization requirements.

6. Global formulation adaptation

Excipients, packaging, alcohol warnings, device requirements, and prescription controls differ by jurisdiction. A U.S. formulation may require adaptation for European, Canadian, or emerging-market registration. Geographic expansion should prioritize markets with established testosterone replacement demand and manageable controlled-substance rules.

How does VOGELXO compare with other testosterone delivery systems?

Delivery system	Main advantage	Main limitation	Excipient opportunity
Testosterone gel	Daily, noninvasive administration	Transfer and daily adherence	Low-transfer, low-irritation, rapid-dry systems
Testosterone injection	High systemic exposure and infrequent dosing for long-acting products	Injections, peaks and troughs, clinic burden	Vehicle tolerability and injection-volume reduction
Testosterone patch	Controlled transdermal delivery	Skin irritation and adhesion failure	Adhesive and permeation optimization
Testosterone pellets	Long duration	Invasive insertion and removal	Limited excipient leverage
Oral testosterone undecanoate	Oral administration	Food effects and systemic safety monitoring	Lipid-based delivery and absorption control
Nasal testosterone	Low transfer risk	Multiple daily administrations and local tolerability	Mucoadhesive and preservative optimization

VOGELXO’s most direct commercial competition is from other testosterone gels. Its broader competition is any product that improves adherence or reduces transfer concerns.

What revenue exposure and launch scenarios apply?

Public FDA and labeling records do not establish VOGELXO-specific revenue exposure. Commercial value should therefore be modeled from prescription volume, average selling price, payer coverage, generic discounting, and the share of patients switching to non-gel testosterone products.

Generic launch scenarios

Scenario	Commercial effect
First generic entry	Rapid price compression and formulary substitution
Multiple generic entrants	Lower margins and limited differentiation
Authorized generic	Preserves channel presence while reducing external substitution
Reformulated branded product	Potentially protects premium pricing if clinical benefits are demonstrated
Device-led differentiation	May preserve prescriber preference despite generic competition
Low-transfer successor	May support switching from older gels and reduce exposure to generic erosion

The highest-value strategy is usually a differentiated successor product launched before price erosion becomes severe. A reformulation without a measurable patient or safety benefit is unlikely to justify a premium.

Key Takeaways

• VOGELXO uses a conventional hydroalcoholic testosterone gel system.
• Its listed excipients are alcohol, carbomer 980, isopropyl myristate, sodium hydroxide, and purified water.
• The existing vehicle is manufacturable but has limited intrinsic differentiation.
• The strongest formulation opportunities are low transfer, lower irritation, alcohol reduction, controlled drying, and metered delivery.
• Topical-product development requires comparative performance, permeation, rheology, stability, and tolerability data.
• Orange Book patents and FDA exclusivity must be reviewed separately from manufacturing know-how and non-listed patent rights.
• Generic competition is the primary price risk; a reformulated successor would need a measurable clinical or handling advantage.
• Device-and-formulation combinations may provide stronger commercial differentiation than excipient substitution alone.

Frequently Asked Questions

Can VOGELXO be reformulated without changing the testosterone strength?

Yes. A sponsor can pursue a different excipient system while retaining testosterone 1%, but the change may affect bioequivalence, absorption, local tolerability, drying time, transfer, and regulatory requirements.

Which excipient is most important in VOGELXO?

The most commercially consequential excipients are alcohol and carbomer 980. Alcohol affects solubility and drying, while carbomer controls viscosity, spreadability, and residence time.

Could an alcohol-free VOGELXO formulation receive patent protection?

Potentially, but the strongest protection would require more than an alcohol substitution. The formulation should demonstrate an unexpected technical result, such as equivalent testosterone exposure with reduced irritation or transfer.

Is a pump better than packets for VOGELXO?

A pump can improve dose consistency and convenience, while packets can provide unit-dose control and portability. The preferred presentation depends on manufacturing cost, patient preference, packaging stability, and transfer-control objectives.

Are testosterone gel excipient patents likely to block generic entry?

They can, particularly when claims cover a specific gel vehicle, delivery device, manufacturing process, or method of reducing transfer. Orange Book listing, claim scope, expiration, and litigation history determine the practical barrier.

References

1. U.S. Food and Drug Administration. (n.d.). Vogelxo (testosterone) gel prescribing information. Upsher-Smith Laboratories, Inc.

2. U.S. Food and Drug Administration. (2022). Topical dermatologic drug product development guidance for industry. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda

4. U.S. Food and Drug Administration. (n.d.). ANDA submissions: Amendments and petition guidance, including Paragraph IV certifications. Center for Drug Evaluation and Research.